Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-04-07
Intellia Therapeutics, Inc.
Intellia is a clinical-stage biotechnology company developing in vivo CRISPR-based gene editing therapies, led by lonvo-z for hereditary angioedema and nex-z for transthyretin amyloidosis.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Pivotal HAE Data Could Create a Real Franchise
The upside rests mostly on one thing: turning a promising gene-editing program into a commercial HAE product on schedule. If that happens, the company can graduate from collaboration revenue to a rare-disease platform with meaningful optionality; if not, the financing and credibility burden returns fast.

Analysis

Thesis
If HAELO is positive and lonvo-z launches in 2027, Intellia can jump from low-quality collaboration revenue to a real rare-disease franchise, with HAE cash flows funding selective ATTR and platform upside; the non-linearity is that one pivotal win can re-rate both the first product and the broader in vivo CRISPR credibility stack.
Last Economy Alignment
AI helps discovery, trial ops and evidence generation, but value still hinges on regulated biology, safety trust and manufacturing rather than software-like scale. Intellia benefits from cheaper cognition without becoming a core AI tollbooth.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.4x (from 5 most recent analyses)
Reasoning
The upside case does not require platform perfection. It mainly requires lonvo-z to take meaningful value from chronic HAE drugs such as Takhzyro and Orladeyo, then add a smaller ATTR contribution against Vyndaqel and Amvuttra plus some licensing revenue. If that happens, investors can value Intellia as a commercial rare-disease company with optionality, not just a milestone-driven CRISPR experiment.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is milestone fragility, not AI commoditization. Lonvo-z must clear HAELO, filing, approval and launch, while nex-z still has to rebuild safety credibility after the 2025 holds. Because Intellia is pre-commercial and concentrated in two lead assets, timeline slips can quickly turn into dilution, weaker payer leverage and a lower strategic multiple.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.27
They own hard-to-copy gene-editing know-how, clinical data and a path toward a one-time treatment, so AI can help them move faster but does not replace what they sell. The risk is simple: biology, regulators and trust still control the pace, and one bad safety surprise can overpower the whole flywheel.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$19.59
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case